文献速递血脂与心血管预防冠心病

脂蛋白(a)升高与家族性高胆固醇血症关联中的确认偏倚

Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

研究比较临床诊断家族性高胆固醇血症(FH)队列(n=391)与英国生物银行基因诊断FH个体(n=37,486)的脂蛋白(a)水平及遗传因素,发现临床FH队列脂蛋白(a)更高,归因于rs10455872-G LPA风险等位基因频率增加(15.1% vs. 8.8%,p<0.05);但FH队列内有无FH致病突变者脂蛋白(a)无差异(1.43 vs. 1.42 log mg/dl,p=0.97),英国生物银行中亦无统计差异。结论提示FH不导致脂蛋白(a)升高,而是脂蛋白(a)升高增加遗传性FH被临床识别的可能性。

要点

  • 临床诊断FH患者脂蛋白(a)升高部分源于LPA风险等位基因频率增加,而非FH本身。
  • 有无FH致病突变者脂蛋白(a)水平无差异,提示存在确认偏倚。
  • 脂蛋白(a)升高与早发冠心病、心血管病家族史及FH诊断相关。

核心结论

  • FH不导致脂蛋白(a)升高,脂蛋白(a)升高增加遗传性FH被临床识别的可能性。

研究设计与样本

  • 比较临床诊断FH队列(n=391)与英国生物银行基因诊断FH个体(n=37,486)的脂蛋白(a)水平及遗传因素。
  • 进行LPA基因型与19,202种表型的全表型关联研究。

主要发现

  • 临床FH队列脂蛋白(a)水平显著高于一般人群或非FH血脂异常患者。
  • 临床FH队列rs10455872-G LPA风险等位基因频率为15.1%,高于8.8%(p<0.05)。
  • FH队列内有无FH致病突变者脂蛋白(a)均值分别为1.43 log mg/dl和1.42 log mg/dl(p=0.97)。
  • 英国生物银行中有无FH致病突变者脂蛋白(a)水平无统计学差异(n=221 vs. 37,486)。
  • LPA基因型与低密度脂蛋白胆固醇升高、心血管病家族史、早发冠心病及FH诊断相关。

临床怎么用

  • 临床诊断FH患者应评估脂蛋白(a)水平,但需注意确认偏倚可能夸大关联。
  • 脂蛋白(a)升高可能促进FH的临床识别,解读FH患者脂蛋白(a)升高时需考虑遗传背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein(a) is an atherogenic low-density lipoprotein-like particle and circulating levels are largely determined by genetics. Patients with familial hypercholesterolemia (FH) have elevated lipoprotein(a); however, it remains unclear why. OBJECTIVES: This study compared the levels of lipoprotein(a) and associated genetic factors between individuals that were ascertained for FH clinically versus genetically. METHODS: We investigated causes of elevated lipoprotein(a) in individuals with clinically diagnosed FH (FH cohort, n = 391) and in individuals with genetically diagnosed FH from the general population (UK Biobank; n = 37,486). RESULTS: Patients in the FH cohort had significantly greater lipoprotein(a) levels than either the general population or non-FH dyslipidemic patients. This was accounted for by increased frequency of the rs10455872-G LPA risk allele (15.1% vs. 8.8%; p < 0.05). However, within the FH cohort, lipoprotein(a) levels did not differ based on the presence or absence of an FH-causing variant (means = 1.43 log mg/dl vs. 1.42 log mg/dl; p = 0.97). Lipoprotein(a) levels were also not statistically different between individuals with and without an FH-causing variant in the UK Biobank cohort, which represents a population sample not biased to cardiovascular ascertainment (n = 221 vs. 37,486). We performed a phenome-wide association study between LPA genotypes and 19,202 phenotypes to demonstrate that elevated lipoprotein(a) is associated with increased low-density lipoprotein cholesterol, a family history of cardiovascular disease, premature coronary artery disease, and a diagnosis of FH. CONCLUSIONS: These results suggest that FH does not cause elevated lipoprotein(a), but that elevated lipoprotein(a) increases the likelihood that an individual with genetic FH will be clinically recognized.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Trinder M, DeCastro ML, Azizi H, et al. Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. J Am Coll Cardiol. 2020. PMID: 32466883. doi:10.1016/j.jacc.2020.03.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。